Vimal Mehta | Chief Executive Officer |
Richard Steinhart | Chief Financial Officer |
Will Kane | Chief Commercial Officer |
Frank Yocca | Chief Scientific Officer |
Vince O’Neill | Chief Medical Officer |
Reina Benabou | Chief Development Officer |
Greg Harrison | Bank of America |
Suzana Princy | Goldman Sachs |
Brian Mills | Jefferies |
Sumant Kulkarni | Canaccord |
Robyn Karnauskas | Truist Securities |
Ram Selvaraju | H.C. Wainwright |
Yatin Suneja | Guggenheim Partners |
Rich | UBS |
Sumant Kulkarni | Canaccord |
Samir Devani | Rx Securities |
Anita Dushyanth | Berenberg Capital Markets |
Good morning and welcome to the BioXcel Therapeutics First Quarter 2021 Financial Results Conference Call. Currently, At this time, all participants are in a listen-only mode. [Operator Instructions] Just to remind everyone certain matters discussed in today’s conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements. The risk factors that may affect results are detailed in the company’s most recent public filings with the US Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, which can be found on its website at www.bioxceltherapeutics.com or on www.sec.gov.